| Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. | neuroblastoma, |
| Amplification of the MYCN oncogene might initiate retinoblastoma in the presence of non-mutated RB1 genes. These unilateral RB1(+/+)MYCN(A) retinoblastomas are characterised by distinct histological features. | retinoblastoma, |
| Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. | retinoblastoma, |
| findings show N-Myc upregulated HDAC5 expression in neuroblastoma cells; HDAC5 repressed NEDD4 gene expression,increased Aurora A gene expression and consequently upregulated N-Myc protein expression;data identify HDAC5 as a novel co-factor in N-Myc oncogenesis | neuroblastoma, |
| Our findings define Sulf-2 as a novel positive regulator of neuroblastoma pathogenicity that contributes to MYCN oncogenicity. | neuroblastoma, |
| Data show that v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) was overexpressed in non-small cell lung cancer (NSCLC) tumor tissues and cell lines, suggesting that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC. | neuroblastoma,lung, |
| Alternative nonhomologous DNA end-joining pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation have been revealed in the process of neuroblastoma initiation in mice. | neuroblastoma, |
| Present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma. At oncogenic levels, MYCN associates with E-box binding motifs in an affinity-dependent manner, binding to strong canonical E-boxes at promoters and invading abundant weaker non-canonical E-boxes clustered at enhancers. | neuroblastoma, |
| Study identified miR-204 as a tumor suppressor miRNA that inhibited a subnetwork of oncogenes strongly associated with MYCN-amplified neuroblastoma and poor patient outcome. MYCN bound to the miR-204 promoter and repressed miR-204 transcription. Conversely, miR-204 directly bound MYCN mRNA and repressed MYCN expression. | neuroblastoma, |
| Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues. | neuroblastoma, |
| [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)]. | neuroblastoma, |
| MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. | neuroblastoma, |
| Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. | neuroblastoma, |
| Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. | neuroblastoma,pediatric, |
| MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children s Oncology Group. | None |
| MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. | None |
| The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. | None |
| Degradation of MYCN oncoprotein by the ubiquitin system. | None |
| N-Myc overexpression is highly oncogenic in mouse myeloid cells | None |
| The MYCN oncogene is a direct target of miR-34a. | None |